Search hospitals > Texas > San Antonio
South Texas Accelerated Research Therapeutics
Claim this profileSan Antonio, Texas 78229
Global Leader in Solid Tumors
Global Leader in Tumors
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
233 reported clinical trials
7 medical researchers
Summary
South Texas Accelerated Research Therapeutics is a medical facility located in San Antonio, Texas. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. South Texas Accelerated Research Therapeutics is involved with conducting 233 clinical trials across 165 conditions. There are 7 research doctors associated with this hospital, such as Amita Patnaik, MD, Drew W Rasco, MD, Kyriakos Papadopoulos, MD, and Kyri Papadopoulos, MD.Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Tumors
Global LeaderStage IV
Stage III
KRAS positive
Top PIs
Amita Patnaik, MDSouth Texas Accelerated Research Therapeutics4 years of reported clinical research
Expert in Tumors
Studies Solid Tumors
18 reported clinical trials
25 drugs studied
Drew W Rasco, MDSouth Texas Accelerated Research Therapeutics (START)8 years of reported clinical research
Expert in Tumors
Studies Solid Tumors
19 reported clinical trials
32 drugs studied
Kyriakos Papadopoulos, MDSouth Texas Accelerated Research Therapeutics2 years of reported clinical research
Studies Solid Tumors
Studies Tumors
7 reported clinical trials
10 drugs studied
Kyri Papadopoulos, MDSouth Texas Accelerated Research Therapeutics6 years of reported clinical research
Studies Squamous Cell Carcinoma
Studies Cancer
2 reported clinical trials
2 drugs studied
Clinical Trials running at South Texas Accelerated Research Therapeutics
Solid Tumors
Tumors
Non-Small Cell Lung Cancer
Cancer
Breast Cancer
Squamous Cell Carcinoma
Pancreatic Cancer
Prostate Cancer
Esophageal Cancer
Bladder Cancer
Pembrolizumab
for Advanced Cancers
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Recruiting2 awards Phase 34 criteria
PM54
for Solid Tumors
This trial is testing a new drug called PM54 to see if it is safe and effective in shrinking tumors and keeping them stable for several months in patients with advanced cancer.
Recruiting1 award Phase 1
SGN-MesoC2
for Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-MesoC2. SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if SGN-MesoC2 is safe and if it works to treat solid tumor cancers.
Recruiting1 award Phase 17 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at South Texas Accelerated Research Therapeutics?
South Texas Accelerated Research Therapeutics is a medical facility located in San Antonio, Texas. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. South Texas Accelerated Research Therapeutics is involved with conducting 233 clinical trials across 165 conditions. There are 7 research doctors associated with this hospital, such as Amita Patnaik, MD, Drew W Rasco, MD, Kyriakos Papadopoulos, MD, and Kyri Papadopoulos, MD.